← Back to Search

Multi-mineral Natural Product

Aquamin for Bad Breath

Phase 2
Recruiting
Led By James Varani
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-reported halitosis
Periodontally stable
Must not have
Diagnosed with any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors) or active gastric / duodenal ulcers - peptic ulcer disease (in last 3 months) or with severe symptoms of ulcerative colitis or Crohn's disease
Coagulopathy/hereditary hemorrhagic disorders/or receiving therapeutic doses of Coumadin or heparin
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days (post-intervention)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if Aquamin®, a mineral supplement from red seaweed, can help people with bad breath by improving their mouth health.

Who is the study for?
This trial is for people with self-reported bad breath who are periodontally stable and can consent to study rules. They must not eat, drink, smoke, or use mouthwash an hour before visits and agree not to scrape their tongue during the study. Women must test negative for pregnancy and use birth control.
What is being tested?
The trial tests if Aquamin®, a natural multi-mineral supplement from red marine algae, reduces halitosis over 90 days. Participants will take Aquamin® and adhere to specific oral hygiene practices throughout the study.
What are the potential side effects?
Potential side effects of Aquamin® aren't specified in this summary but considering it's a natural mineral product, they may be minimal compared to pharmaceuticals; however, participants should report any adverse reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I believe I have bad breath.
Select...
My gums are healthy and do not have any major issues.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with stomach or intestinal bleeding disorders recently.
Select...
I have a bleeding disorder or am on blood thinners like Coumadin or heparin.
Select...
I have untreated cavities, gum disease, or other oral conditions causing bad breath.
Select...
I do not have any gastrointestinal, colon cancer, kidney disease, or high calcium levels.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days (post-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days (post-intervention) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Halitosis Associated Life-quality Test (HALT) questionnaire (modified)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Aquamin®Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aquamin
2021
Completed Phase 2
~40

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for bad breath include maintaining good oral hygiene, using antimicrobial mouthwashes, and dietary supplementation. Good oral hygiene practices, such as regular brushing and flossing, help remove food particles and plaque that harbor bacteria responsible for bad breath. Antimicrobial mouthwashes, like those containing chlorhexidine, reduce the bacterial load in the mouth, thereby decreasing the production of foul-smelling compounds. Dietary supplements, such as Aquamin® (a multi-mineral product from red marine algae), may improve oral health by providing essential minerals that strengthen teeth and gums, potentially reducing the bacterial biofilm and inflammation associated with halitosis. These treatments are crucial for bad breath patients as they address the underlying causes of halitosis, leading to improved oral health and fresher breath.

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,853 Previous Clinical Trials
6,433,015 Total Patients Enrolled
James VaraniPrincipal InvestigatorUniversity of Michigan
2 Previous Clinical Trials
73 Total Patients Enrolled
Muhammad N AslamStudy DirectorUniversity of Michigan
2 Previous Clinical Trials
73 Total Patients Enrolled

Media Library

Aquamin (Multi-mineral Natural Product) Clinical Trial Eligibility Overview. Trial Name: NCT05058638 — Phase 2
Bad Breath Research Study Groups: Aquamin®
Bad Breath Clinical Trial 2023: Aquamin Highlights & Side Effects. Trial Name: NCT05058638 — Phase 2
Aquamin (Multi-mineral Natural Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05058638 — Phase 2
Bad Breath Patient Testimony for trial: Trial Name: NCT05058638 — Phase 2
~2 spots leftby Jul 2025